BioSpace13h
The Search for the Next Keytruda: Immuno-Oncology’s Next Play
More than a decade after Merck’s Keytruda and BMS’ Yervoy ushered in the immuno-oncology revolution, the space is at a ...
Exelixis focuses on future growth despite COSMIC-313 trial challenges
Genitourinary Cancer Symposium 2025, held on 13-15 February, final results from the randomised, multicentre, double-blind, ...
Daily4d
Bristol Myers Squibb application for Opdivo Plus Yervoy for MSI-H/ dMMR colorectal cancer accepted by USFDA
Bristol Myers Squibb has announced that the U.S. Food and Drug Administration (FDA) has accepted the supplemental biologics ...
Cure Today5d
FDA Accepts sBLA For Opdivo Plus Yervoy For Some Patients with mCRC
The FDA accepted a supplemental biologics license application for Opdivo plus Yervoy as a first-line treatment for some adult ...
Why Bristol-Myers Squibb Co (BMY) Went Up On Monday?
In this article, we are going to take a look at where Bristol-Myers Squibb Co (NYSE:BMY) stands against other stocks that ...
FDA accepts BMS’ Opdivo-Yervoy combo sBLA for colorectal cancer
The US Food and Drug Administration (FDA) has accepted Bristol Myers Squibb’s (BMS) supplemental biologics licence ...
Cancer Therapy Advisor6d
Nivolumab + Ipilimumab Under Review for First-Line Treatment of MSI-H/dMMR CRC
The FDA has accepted the sBLA for nivolumab (Opdivo) plus ipilimumab (Yervoy) as a potential first-line treatment for advanced MSI-H or dMMR CRC.
10 Stocks Grow Firmer Despite Mixed Market Sentiment
Bristol-Myers saw its share prices grow by 3.67 percent on Monday to finish at $57.88 apiece as investors cheered news of the ...